Angel News

Angel News

Back to Homepage

14th August 2018

Artios completes £65m Series B investment round

Arix Bioscience plc, a global healthcare and life science company supporting medical innovation, has announced that its Group Business Artios Pharma Limited, a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, has completed an oversubscribed £65 million Series B financing following strong interest from investors.


Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:




Enter the characters in the image shown:

Back to Homepage